"Tardive Dyskinesia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug-related movement disorder characterized by uncontrollable movements in certain muscles. It is associated with a long-term exposure to certain neuroleptic medications (e.g., METOCLOPRAMIDE).
Descriptor ID |
D000071057
|
MeSH Number(s) |
C10.228.662.262.500.500 C10.597.350.275.500 C23.888.592.350.275.500
|
Concept/Terms |
Tardive Dyskinesia- Tardive Dyskinesia
- Dyskinesia, Tardive
- Dyskinesias, Tardive
- Tardive Dyskinesias
- Tardive Dystonia
- Dystonia, Tardive
- Dystonias, Tardive
- Tardive Dystonias
|
Below are MeSH descriptors whose meaning is more general than "Tardive Dyskinesia".
Below are MeSH descriptors whose meaning is more specific than "Tardive Dyskinesia".
This graph shows the total number of publications written about "Tardive Dyskinesia" by people in this website by year, and whether "Tardive Dyskinesia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 9 | 0 | 9 |
2018 | 7 | 0 | 7 |
2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tardive Dyskinesia" by people in Profiles.
-
Crushing of deutetrabenazine tablets limited to individual case. Am J Health Syst Pharm. 2021 08 30; 78(17):1552-1553.
-
On crushing of deutetrabenazine tablets. Am J Health Syst Pharm. 2021 08 30; 78(17):1551-1552.
-
Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia. J Comp Eff Res. 2019 10; 8(13):1077-1088.
-
Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study. J Clin Psychiatry. 2018 12 18; 80(1).
-
The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. J Affect Disord. 2019 03 01; 246:217-223.
-
Tardive Myoclonic Dyskinesia Responsive to Sodium Oxybate. Clin Neuropharmacol. 2018 Sep/Oct; 41(5):194-196.
-
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018; 12:1215-1238.
-
Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop. J Clin Psychiatry. 2018 May/Jun; 79(3).
-
Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis. J Clin Psychiatry. 2018 Mar/Apr; 79(2).
-
Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018 06 15; 389:21-27.